
Results
3
Companies which are more than 50% undervalued based on analyst price target.
3 companies
Ryvu Therapeutics
Market Cap: zł320.0m
A clinical-stage drug discovery and development company, engages in developing of small molecule therapies for treatment in oncology in Poland, European Union, and internationally.
RVU
zł13.90
7D
-2.7%
1Y
-56.8%
Molecure
Market Cap: zł115.2m
A biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland.
MOC
zł5.44
7D
-4.4%
1Y
1.1%
Poltreg
Market Cap: zł112.4m
A biotechnology company, researches and develops therapies for autoimmune diseases.
PTG
zł19.00
7D
5.6%
1Y
-39.5%